Heidebrecht Hans-Jürgen, Toro-Sierra José, Kulozik Ulrich
Chair for Food and Bioprocess Engineering, Technical University of Munich, Weihenstephaner Berg 1, 85354 Freising, Germany.
Kraft Foods R&D Inc./Mondelēz International GmbH, 82008 Unterhaching, Germany.
Foods. 2018 Jun 28;7(7):101. doi: 10.3390/foods7070101.
The use of bioactive bovine milk immunoglobulins (Ig) has been found to be an alternative treatment for certain human gastrointestinal diseases. Some methodologies have been developed with bovine colostrum. These are considered in laboratory scale and are bound to high cost and limited availability of the raw material. The main challenge remains in obtaining high amounts of active IgG from an available source as mature cow milk by the means of industrial processes. Microfiltration (MF) was chosen as a process variant, which enables a gentle and effective concentration of the Ig fractions (ca. 0.06% in raw milk) while reducing casein and lactose at the same time. Different microfiltration membranes (ceramic standard and gradient), pore sizes (0.14⁻0.8 µm), transmembrane pressures (0.5⁻2.5 bar), and temperatures (10, 50 °C) were investigated. The transmission of immunoglobulin G (IgG) and casein during the filtration of raw skim milk (<0.1% fat) was evaluated during batch filtration using a single channel pilot plant. The transmission levels of IgG (160 kDa) were measured to be at the same level as the reference major whey protein β-Lg (18 kDa) at all evaluated pore sizes and process parameters despite the large difference in molecular mass of both fractions. Ceramic gradient membranes with a pore sizes of 0.14 µm showed IgG-transmission rates between 45% to 65% while reducing the casein fraction below 1% in the permeates. Contrary to the expectations, a lower pore size of 0.14 µm yielded fluxes up to 35% higher than 0.2 µm MF membranes. It was found that low transmembrane pressures benefit the Ig transmission. Upscaling the presented results to a continuous MF membrane process offers new possibilities for the production of immunoglobulin enriched supplements with well-known processing equipment for large scale milk protein fractionation.
已发现使用具有生物活性的牛乳免疫球蛋白(Ig)是治疗某些人类胃肠道疾病的一种替代方法。人们已开发出一些用牛初乳的方法。这些方法仅在实验室规模下可行,而且成本高昂,原材料供应有限。主要挑战仍然是通过工业流程从成熟牛奶这种可用来源中获取大量活性IgG。微滤(MF)被选为一种工艺变体,它能在降低酪蛋白和乳糖含量的同时,温和且有效地浓缩Ig组分(生乳中约为0.06%)。研究了不同的微滤膜(陶瓷标准膜和梯度膜)、孔径(0.14 - 0.8微米)、跨膜压力(0.5 - 2.5巴)和温度(10、50摄氏度)。在使用单通道中试装置进行间歇过滤期间,评估了脱脂生乳(脂肪含量<0.1%)过滤过程中免疫球蛋白G(IgG)和酪蛋白的透过率。尽管两种组分的分子量差异很大,但在所有评估的孔径和工艺参数下,测得IgG(约160 kDa)的透过率与参考主要乳清蛋白β-Lg(约18 kDa)处于同一水平。孔径为0.14微米的陶瓷梯度膜显示IgG透过率在45%至65%之间,同时使透过液中的酪蛋白组分降低至1%以下。与预期相反,0.14微米的较小孔径产生的通量比0.2微米的微滤膜高出35%。研究发现,低跨膜压力有利于Ig的透过。将所呈现的结果扩大到连续微滤膜工艺,为使用用于大规模乳蛋白分级分离的知名加工设备生产富含免疫球蛋白的补充剂提供了新的可能性。